Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

By Bishton Mark J.   Johnstone Ricky W.   Dickinson Michael   Harrison Simon   Prince H. Miles  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2674-2688

MDPI

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors as Anticancer Drugs

By Eckschlager Tomas   Plch Johana   Stiborova Marie   Hrabeta Jan  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1414-1414

MDPI

Access to resources Recommend Favorite

Clinical Toxicities of Histone Deacetylase Inhibitors

By Subramanian Srividya   Bates Susan E.   Wright John J.   Espinoza-Delgado Igor   Piekarz Richard L.  

Pharmaceuticals, Vol. 3, Iss. 9, 2010-08 ,pp. : 2751-2767

MDPI

Access to resources Recommend Favorite

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

By Chhabra Saurabh  

Pharmaceuticals, Vol. 10, Iss. 2, 2017-04 ,pp. : 40-40

MDPI

Access to resources Recommend Favorite

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies

By Schmeel Frederic Carsten   Schmeel Leonard Christopher   Gast Sanna-Marie   Schmidt-Wolf Ingo G. H.  

International Journal of Molecular Sciences, Vol. 15, Iss. 8, 2014-08 ,pp. : 14632-14648

MDPI

Access to resources Recommend Favorite